Gyre Therapeutics, Inc. Additional Paid in Capital
Gyre Therapeutics, Inc. (GYRE) had Additional Paid in Capital of $240.64 million as of 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest › Equity, Attributable to Parent
us-gaap:AdditionalPaidInCapital · last filed 2026-08-07
- 2026-06-30: Additional Paid in Capital $240.64M.
- 2026-03-31: Additional Paid in Capital $174.65M.
- 2025-12-31: Additional Paid in Capital $172.82M; Additional Paid in Capital as first filed $172.05M.
- 2025-09-30: Additional Paid in Capital $167.13M.
| Period end | Additional Paid in Capital | Additional Paid in Capital as first filed |
|---|---|---|
| 2026-06-30 | $240.64M 10-Q · filed 2026-08-07 | |
| 2026-03-31 | $174.65M 10-Q · filed 2026-05-08 | |
| 2025-12-31 | $172.82M 10-Q · filed 2026-08-07 | $172.05M 10-K · filed 2026-03-13 |
| 2025-09-30 | $167.13M 10-Q · filed 2025-11-07 | |
| 2025-06-30 | $161.44M 10-Q · filed 2025-08-11 | |
| 2025-03-31 | $138.18M 10-Q · filed 2025-05-09 | |
| 2024-12-31 | $136.19M 10-K · filed 2026-03-13 | |
| 2024-09-30 | $134.30M 10-Q · filed 2024-11-13 | |
| 2024-06-30 | $133.66M 10-Q · filed 2024-08-13 | |
| 2024-03-31 | $133.20M 10-Q · filed 2024-05-13 | |
| 2023-12-31 | $68.18M 10-K · filed 2025-03-17 | |
| 2023-09-30 | $384.89M 10-Q · filed 2023-10-26 | |
| 2023-06-30 | $384.80M 10-Q · filed 2023-08-14 | |
| 2023-03-31 | $384.69M 10-Q · filed 2023-05-15 | |
| 2022-12-31 | $32.80M 10-K · filed 2024-03-27 | $389.21M 10-K · filed 2023-03-30 |
| 2022-09-30 | $399.83M 10-Q · filed 2022-11-14 | |
| 2022-06-30 | $444.63M 10-Q · filed 2022-08-15 | |
| 2022-03-31 | $444.28M 10-Q · filed 2022-05-09 | |
| 2021-12-31 | $443.75M 10-K · filed 2023-03-30 | |
| 2021-09-30 | $443.07M 10-Q · filed 2021-11-12 | |
| 2021-06-30 | $442.26M 10-Q · filed 2021-08-05 | |
| 2021-03-31 | $441.25M 10-Q · filed 2021-05-06 | |
| 2020-12-31 | $390.80M 10-K · filed 2022-03-31 | |
| 2020-09-30 | $389.88M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $388.72M 10-Q · filed 2020-08-06 | |
| 2020-03-31 | $359.94M 10-Q · filed 2020-05-11 | |
| 2019-12-31 | $326.81M 10-K · filed 2021-03-04 | |
| 2019-09-30 | $326.14M 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $325.25M 10-Q · filed 2019-08-01 | |
| 2019-03-31 | $324.21M 10-Q · filed 2019-05-02 | |
| 2018-12-31 | $323.28M 10-K · filed 2020-02-20 | |
| 2018-09-30 | $322.47M 10-Q · filed 2018-11-01 | |
| 2018-06-30 | $321.76M 10-Q · filed 2018-08-02 | |
| 2018-03-31 | $321.17M 10-Q · filed 2018-05-03 | |
| 2017-12-31 | $204.26M 10-K · filed 2019-03-08 | |
| 2017-09-30 | $192.62M 10-Q · filed 2017-11-02 | |
| 2017-06-30 | $192.29M 10-Q · filed 2017-08-03 | |
| 2017-03-31 | $165.95M 10-Q · filed 2017-05-11 | |
| 2016-12-31 | $164.05M 10-K · filed 2018-03-19 | |
| 2016-09-30 | $163.82M 10-Q · filed 2016-11-03 | |
| 2016-06-30 | $162.92M 10-Q · filed 2016-08-04 | |
| 2016-03-31 | $162.60M 10-Q · filed 2016-05-05 | |
| 2015-12-31 | $162.46M 10-K · filed 2017-03-08 | $162.45M 10-K · filed 2016-03-09 |
| 2015-09-30 | $162.09M 10-Q · filed 2015-11-05 | |
| 2015-06-30 | $7.01M 8-K/A · filed 2015-10-23 | $423.83M 10-Q · filed 2015-07-31 |
| 2015-03-31 | $423.18M 10-Q · filed 2015-05-07 | |
| 2014-12-31 | $6.92M 10-K · filed 2016-03-09 | $422.30M 10-K · filed 2015-03-16 |
| 2014-09-30 | $421.45M 10-Q · filed 2014-11-06 | |
| 2014-06-30 | $420.64M 10-Q · filed 2014-08-07 | |
| 2014-03-31 | $419.63M 10-Q · filed 2014-05-08 | |
| 2013-12-31 | $6.64M 8-K/A · filed 2015-10-23 | $415.12M 10-K · filed 2014-03-14 |
| 2013-09-30 | $413.87M 10-Q · filed 2013-11-06 | |
| 2013-06-30 | $412.53M 10-Q · filed 2013-08-07 | |
| 2013-03-31 | $411.23M 10-Q · filed 2013-05-08 | |
| 2012-12-31 | $409.61M 10-K · filed 2014-03-14 | |
| 2012-09-30 | $408.22M 10-Q · filed 2012-11-08 | |
| 2012-06-30 | $406.31M 10-Q · filed 2012-08-09 | |
| 2012-03-31 | $403.11M 10-Q · filed 2012-05-09 | |
| 2011-12-31 | $401.15M 10-K · filed 2013-03-15 | |
| 2011-09-30 | $399.12M 10-Q · filed 2011-11-03 | |
| 2011-06-30 | $396.94M 10-Q · filed 2011-08-09 | |
| 2010-12-31 | $309.99M 10-K · filed 2012-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |